Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease
October 09 2019 - 7:00AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) diseases, today announced the initiation of the ATTENTION-AD,
a long-term extension study for patients with Early Alzheimer’s
disease and treated with ANAVEX®2-73 (blarcamesine).
The ATTENTION-AD study (Open
Label Extension
Study for Patients with Early
Alzheimer’s Disease (AD) Enrolled
in Study ANAVEX2-73-AD-004),
which is an extension of the Phase 2b/3 ANAVEX®2-73-AD-004 clinical
study currently underway, will give AD patients an opportunity to
continue their treatment. This study is expected to last two years
for patients included in the ANAVEX®2-73-AD-004 study, once they
have completed the placebo-controlled 48-week Phase 2b/3 trial.
ATTENTION-AD will be conducted in parallel with
the Phase 2b/3 ANAVEX®2-73-AD-004 study.All patients who
participate in the Phase 2b/3 ANAVEX®2-73-AD-004 study will be
eligible to participate also in the ATTENTION-AD study under a
voluntary open label extension protocol.
“This is an important development as the
patients who have completed the main study, ANAVEX2-73-AD-004, are
consistently expressing the wish to gain ongoing access to this
investigational therapy,” says A/Professor Stephen Macfarlane,
FRANZCP, Head of Clinical Services at the Dementia Centre,
HammondCare and Principal Investigator for both studies.
“People living with Alzheimer’s disease
desperately need new therapies and ATTENTION-AD reflects our
commitment to the patients who participated in the Phase 2b/3
ANAVEX®2-73-AD-004 study and who have contributed enormously to the
development of a potential new medicine for patients with Early
Alzheimer’s disease,” said Christopher U Missling, PhD, Chief
Executive Officer of Anavex. “This study will provide supplemental
data on ANAVEX®2-73 (blarcamesine).”
About Alzheimer’s Disease
Alzheimer's disease is a progressive,
irreversible neurological disease and the most common cause of
dementia. In the U.S., there are over five million individuals
living with Alzheimer's disease and an estimated 50 million people
live with dementia worldwide. Today, there are no commercially
available therapies to address the underlying cause of Alzheimer's.
According to the World Alzheimer Report 2019, the current annual
cost of dementia is estimated at $1 trillion, a figure set to
double by 2030.1
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders including
Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other
central nervous system (CNS) diseases, pain and various types of
cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine),
recently completed a successful Phase 2a clinical trial for
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally
available drug candidate that restores cellular homeostasis by
targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited
anticonvulsant, anti-amnesic, neuroprotective and anti-depressant
properties in animal models, indicating its potential to treat
additional CNS disorders, including epilepsy. The Michael J. Fox
Foundation for Parkinson’s Research previously awarded Anavex a
research grant, which fully funded a preclinical study to develop
ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s
disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic
receptors, is a promising preclinical drug candidate demonstrating
disease-modifying activity against the major hallmarks of
Alzheimer’s disease in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies. In preclinical
trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial
dysfunction and neuroinflammation. Further information is available
at www.anavex.com. You can also connect with the company
on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:
Anavex Life Sciences Corp.Research &
Business DevelopmentToll-free: 1-844-689-3939Email:
info@anavex.com
Investors & Media:Email:
ir@anavex.com
____________1
https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jul 2023 to Jul 2024